Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Deferoxamine in Intracerebral Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and ≤ 80 years~2. The diagnosis of ICH is confirmed by brain CT scan~3. NIHSS score ≥ 6 and GCS \> 6 upon presentation~4. The first dose of the study drug can be administered within 24h of ICH symptom onset~5. Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1~6. Signed and dated informed consent is obtained.~Exclusion Criteria:~1. Previous chelation therapy or known hypersensitivity to DFO products~2. Known severe iron deficiency anemia (defined as hemoglobin concentration \< 7g/dL or requiring blood transfusions)~3. Abnormal renal function, defined as serum creatinine \> 2 mg/dL~4. Planned surgical evacuation of ICH prior to administration of study drug (placement of a catheter for ventricular drainage is not a contraindication to enrollment)~5. Suspected secondary ICH related to tumour, ruptured aneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemic infarct, or venous sinus thrombosis~6. Infratentorial hemorrhage~7. Irreversibly impaired brainstem function (bilateral fixed and dilated pupils and extensor motor posturing)~8. Complete unconsciousness, defined as a score of 3 on item 1a of the NIHSS (Responds only with reflex motor or autonomic effects or totally unresponsive, and flaccid)~9. Pre-existing disability, defined as pre-ICH mRS ≥ 2~10. Coagulopathy - defined as elevated aPTT or INR \>1.3 upon presentation; concurrent use of direct thrombin inhibitors (such as dabigatran), direct factor Xa inhibitors (such as rivaroxaban), or low-molecular-weight heparin~11. Taking iron supplements containing ≥ 325 mg of ferrous iron, or prochlorperazine~12. Patients with heart failure taking \> 500 mg of vitamin C daily~13. Known severe hearing loss~14. Known pregnancy, or positive pregnancy test, or breastfeeding~15. Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause~16. Positive drug screen for cocaine upon presentation~17. Any condition which, in the judgement of the investigator, might increase the risk to the patient~18. Life expectancy of less than 90 days due to comorbid conditions~19. Concurrent participation in another research protocol for investigation of another experimental therapy~20. Indication that a new Do Not Resuscitate (DNR) or Comfort Measures Only (CMO) order will be implemented within the first 72 hours of hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Deferoxamine (Type: ACTIVE_COMPARATOR): Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
- Normal Saline (Type: PLACEBO_COMPARATOR): 0.9% sodium chloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues